tradingkey.logo

BRIEF-Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression

ReutersFeb 18, 2025 10:42 PM

- Supernus Pharmaceuticals Inc SUPN.O:

  • SUPERNUS ANNOUNCES TOPLINE RESULTS FROM PHASE 2B STUDY IN ADULTS WITH TREATMENT RESISTANT DEPRESSION

  • SUPERNUS PHARMACEUTICALS INC - PHASE 2B STUDY OF SPN-820 IN TRD FAILS PRIMARY ENDPOINT

  • SUPERNUS PHARMACEUTICALS INC - SPN-820 SAFETY PROFILE CONSISTENT WITH PREVIOUS TRIALS

Source text: ID:nGNX7YJMG2

Further company coverage: SUPN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI